ASLN News and Press, ASLAN Pharmaceuticals Limited From 11/03/23

Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab ’s differentiated effects of targeting IL-13R vs IL-4R Using an established COPD model of human lung slices, new data demonstrate eblasakimab &...

2023-10-27 09:20:12 ET More on ASLAN Pharmaceuticals Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical earnings data for ASLAN Pharmaceuticals Financial information for ASLAN Pharmaceuticals For further details see: ASLAN Pharmaceuti...

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis , met the primary endpoint across three dosing arms; the study established eblasakimab’s potential to deliver a monthly dosing re...

FNCB Bancorp Inc. (FNCB) is expected to report for Q1 2024 Civista Bancshares Inc. (CIVB) is expected to report $0.6 for Q3 2023 ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023 Grupo Televisa S.A. (TV) is expected to report $0.02 for Q3 2023 Red River...

ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023

Discussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab’s Introduction” A...

ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveys Register here to attend the webinar event on October 24, 2023 at 11:00 am ET SAN MATEO, Calif. and SINGAPOR...

Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate e blasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation Ne...

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that four abstracts on eblasakimab and ...

SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person comp...